Flow Cytometry Interpretation Report

Patient Name: [Patient full name]

MRN: [Medical record number]

Date of Birth: [Date of birth]

Accession Number: [Accession number]

Specimen Collection Date: [Collection date and time]

Report Date: [Report date]

Ordering Clinician: [Ordering clinician name and credentials]

Performing Laboratory: [Laboratory name and location]

(Use explicit null conventions where information is missing: "Not provided" for information not received with the requisition, "Not available" for information expected but unknown, and "Not applicable" when it does not apply. Do not infer clinical indication or specimen source if not specified.)

Clinical Indication

[Reason for flow cytometry and relevant clinical history] (State the clinical question such as evaluation of cytopenias, lymphoma/leukemia assessment, blast evaluation, or MRD assessment. Include known diagnosis and relevant therapy status when provided, such as targeted therapy exposure or transplant status. If clinical history is not provided, state: "Clinical indication: Not provided.")

[Prior relevant flow cytometry studies, if available] (Include prior accession number and date, and note whether the current abnormal population is phenotypically similar, shows therapy-related antigen modulation, or differs. Omit this line if no prior studies are available or relevant.)

Specimen

• Specimen type and source: [Specimen type and anatomic site when applicable] (Do not infer if unspecified.)
• Viability: [Viability percentage % / Not assessed]
• Adequacy: [Adequate / Limited (reason) / Unsatisfactory (reason)]
• Specimen condition issues: [Clotting / Hemodilution / Low cellularity / Delayed transport / High debris / None identified] (Include only issues present that may affect interpretation.)

Method

• Assay: Multiparameter flow cytometry immunophenotyping
• Panels performed: (List markers by tube or cocktail; distinguish surface versus cytoplasmic markers when relevant.)
  • Tube [#]/Panel [name]: [Marker1 (surface)]; [Marker2 (cytoplasmic)]; [Marker3]; [...]
  • (Repeat tubes/panels as needed.)
• Gating strategy: [Brief description of gating backbone, e.g., debris exclusion and viability gating followed by CD45 vs SSC to identify major compartments]
• Parent population for quantitation: [e.g., Viable CD45+ events]
• Total acquired events: [Total events acquired] (Note if below threshold for optimal sensitivity, particularly for MRD or rare-event detection.)

Results

Population Summary

(Provide a concise quantitative overview of major compartments as percentages of the specified parent gate. Include only compartments that were evaluated.)

• Parent gate: [Parent population used for quantitation]
• Blasts: [Percent %]
• Lymphocytes: [Percent %]
• Monocytes: [Percent %]
• Granulocytes: [Percent %]
• Plasma cells: [Percent %] (Include only if evaluated.)

Abnormal Populations

(Create a separate subsection for each abnormal population. If none are identified, include the negative findings statement below instead.)

Abnormal Population [#]: [Lineage/descriptor]

• Quantitation: [Percent % of total events]; [Percent % of relevant parent gate]
• Lineage: [B-cell / T-cell / NK-cell / Plasma cell / Myeloid / Blast]
• Immunophenotype:
  • Positive: [List markers with intensity qualifiers: bright/dim/partial as applicable]
  • Negative: [List markers]
  • Light chain status: [Kappa restricted / Lambda restricted / Polytypic / Noncontributory]
• Aberrant expression: [Describe aberrancies explicitly, or state "None identified"]
• Interpretation: [Concise statement linking the phenotype to a diagnostic category or differential diagnosis; recommend correlation with morphology and ancillary studies as needed.]

(Repeat abnormal population subsection for each additional population identified.)

Negative findings: [Statement specifying no immunophenotypic evidence of clonal or abnormal population and which compartments were adequately evaluated] (Use only when no abnormal populations are identified. Avoid absolute exclusion language; use "No immunophenotypic evidence by flow cytometry of..." with limitations noted.)

Minimal Residual Disease (MRD) Assessment

(Include this subsection only if MRD analysis was specifically requested and performed.)

• Target population/diagnosis: [Target]
• Approach: [LAIP-based / DfN-based / Other]
• Sensitivity/LOD: [Stated assay sensitivity or detection limit] (Note any constraints due to low event count.)
• Result: [Detected at percent % of parent gate / Not detected] (Include uncertainty qualifiers when appropriate.)

Diagnostic Impression

[Overall interpretive summary prioritizing clinically significant findings] (Use appropriate certainty language such as "Findings consistent with," "support," or "suggest" based on the strength of evidence. When flow cytometry alone is insufficient for definitive classification, state that correlation with morphology and ancillary studies is required. If multiple abnormalities are present, clarify whether they appear related or separate.)

Limitations and Recommendations

Limitations: [Specimen quality issues / Analytical limitations / Sensitivity limitations / Clinical history not provided] (Include only applicable limitations. Omit this line if none apply.)

Recommendations: [Correlate with morphology/histology; correlate with cytogenetics/FISH and/or molecular testing; consider repeat sampling if inadequate; urgent confirmatory testing for time-sensitive patterns] (Include only applicable recommendations.)

Critical Result Communication

(Include this section only when a critical result was communicated.)

• Date/time: [Date and time of communication]
• Recipient: [Name and role]
• Method: [Phone / Secure message]
• Communicator: [Name and credentials]
• Reason: [Brief description of critical finding]

Sign-Out

Interpreting Pathologist: [Name, degrees/credentials]

[Electronic signature] [Signature date/time]

(Include regulatory or LDT disclaimers only if required by institutional policy for this specific assay.)